Recorded fact · drug.label_indication
drug.label_indication for empagliflozin-metformin-hcl|chronic-kidney-disease
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact a52e535f resolves to.
The record
| Fact id | a52e535fbdd3cc1bca74d4e7 |
|---|---|
| Entity | drug: empagliflozin-metformin-hcl|chronic-kidney-disease |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260825 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: ca6f178606d9e2b4758ce4762633ea47217e7c98fa932e55c113ea288e7964d5.
The value
{
"ingredient": "Empagliflozin/Metformin HCl",
"conditionId": "chronic-kidney-disease",
"conditionName": "Chronic Kidney Disease",
"matchedAlias": "chronic kidney disease",
"context": "indication",
"brand": "Synjardy",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "0fdd0255-0055-65f3-b2c0-db8fbb87beae",
"labelEffectiveTime": "20260825",
"labelsRead": 2,
"labelsNaming": 2,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: bef5f88fa6edc8a0d52306ba483aac3e6ea061ee8d550127c99422164ad938b0.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.